RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
NCT00101972
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
53
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
BIOLOGICAL:
monoclonal antibody RAV12
Sponsor
MacroGenics